583 related articles for article (PubMed ID: 21358697)
1. SGLT2 inhibitors: molecular design and potential differences in effect.
Isaji M
Kidney Int Suppl; 2011 Mar; (120):S14-9. PubMed ID: 21358697
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
3. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Chen LH; Leung PS
Diabetes Obes Metab; 2013 May; 15(5):392-402. PubMed ID: 23331516
[TBL] [Abstract][Full Text] [Related]
6. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN
Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
[TBL] [Abstract][Full Text] [Related]
7. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
8. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA
Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
[TBL] [Abstract][Full Text] [Related]
10. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
11. Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents.
Zhang Y; Ban H; Yu R; Wang Z; Zhang D
Future Med Chem; 2018 May; 10(10):1261-1276. PubMed ID: 29749749
[TBL] [Abstract][Full Text] [Related]
12. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
List JF; Whaley JM
Kidney Int Suppl; 2011 Mar; (120):S20-7. PubMed ID: 21358698
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
Choi CI
Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
[TBL] [Abstract][Full Text] [Related]
15. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent.
Nomura S
Curr Top Med Chem; 2010; 10(4):411-8. PubMed ID: 20180760
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
Kashiwagi A; Maegawa H
J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
[TBL] [Abstract][Full Text] [Related]
17. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
Washburn WN; Poucher SM
Expert Opin Investig Drugs; 2013 Apr; 22(4):463-86. PubMed ID: 23452053
[TBL] [Abstract][Full Text] [Related]
18. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
[TBL] [Abstract][Full Text] [Related]
19. Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ
Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
[TBL] [Abstract][Full Text] [Related]
20. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
